Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.36 USD
+0.07 (5.43%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.35 -0.01 (-0.74%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.36 USD
+0.07 (5.43%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.35 -0.01 (-0.74%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Zacks News
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 4.17% and 7.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers
by Zacks Equity Research
Exelixis (EXEL) collaborates with Bristol Myers to evaluate its next-generation tyrosine kinase inhibitor in combination with immuno-oncology therapies in advanced solid tumors.
Nektar (NKTR) Moves 8.5% Higher: Will This Strength Last?
by Zacks Equity Research
Nektar (NKTR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 5.56% and -18.18%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline
by Zacks Equity Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nektar (NKTR) Down 10.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On Track
by Zacks Equity Research
Nektar (NKTR) reports encouraging fourth-quarter 2020 results. The company plans to initiate a new registrational study on its lead pipeline candidate, bempegaldesleukin, in 2021.
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy
Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Incyte (INCY) and Nektar (NKTR).
Is a Surprise Coming for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
Nektar (NKTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Nektar (NKTR) Teams Up With Merck for Head & Neck Cancer Study
by Zacks Equity Research
Nektar's (NKTR) shares up following a deal with Merck for a combination study of bempegaldesleukin with Keytruda for advanced head and neck cancer study.
Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.
Nektar (NKTR) Begins Dosing in NKTR-255 Study for Two Cancers
by Zacks Equity Research
Nektar (NKTR) doses the first patient in a phase I/II study on NKTR-255 in combination with Erbitux for treating head and neck squamous cell carcinoma or colorectal cancer. Shares up.
Why Is Nektar (NKTR) Up 3% Since Last Earnings Report?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar (NKTR) Stock Up 3% on Q3 Earnings and Revenue Beat
by Zacks Equity Research
Nektar (NKTR) reports encouraging third-quarter 2020 results. Enrollment in clinical studies back on track.
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 23.75% and 39.34%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nektar (NKTR) Down 12% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress
by Zacks Equity Research
Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 34.78% and 113.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Nektar Therapeutics (NKTR) Q2 Earnings Expected to Decline
by Zacks Equity Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.